2023-03-13 07:02:06 ET
Teleflex ( NYSE: TFX ) reported new research from controlled and real-world studies of Prostatic Urethral Lift (PUL) procedure with its UroLift System to treat men with benign prostatic hyperplasia (BPH)
The company said the results showed the benefits of early intervention with respect to durability, symptom improvement and sexual function which urologists expect from the the device to treat BPH - also called an enlarged prostate.
Data from over 330 PUL individuals studied in a controlled setting showed that, PUL with UroLift was durable in most people at one and five years, according to the company.
Teleflex added that lower durability at one year is linked with undertreatment (?4 implants placed). Lower durability at 5 years is affected by poor baseline obstructive symptoms indicated by the International Prostate Symptom Score (IPSS)
"These important new analyses show that, whether compared to other interventions or medication, the UroLift System offers unique benefits that make it the treatment of choice for many men searching for long-term relief of burdensome BPH symptoms," said Jacqueline Welch, vice president, Global Clinical and Scientific Operations, Teleflex.
The company presented the research at the 38 th Annual European Association of Urology (EAU) Congress in Milan.
For further details see:
Teleflex highlights benefits of UroLift System for enlarged prostate